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Abstract
LUMO-lowering organocatalysis has been extended to promote the conjugate addition of S-alkyl
and -pyrrolyl silylketene acetals to α,β-unsaturated aldehydes, yielding both, syn and anti
Mukaiyama–Michael products with high levels of enantioselectivity. This strategy allows for the
generation of chemically useful 1,5-dicarbonyl systems and again highlights the utility of
organocatalysis.
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1. Introduction
Since its discovery in 1974, the Mukaiyama–Michael reaction has become a powerful
chemical tool for carbon–carbon fragment couplings with the accompanying formation of
vicinal carbon-sp3 stereochemistry.1 During this time, the inherent selectivity of latent
enolates (such as silylketene acetals and enol silanes) to undergo conjugate addition to
unsaturated ketones, imides and esters in the presence of Lewis acids has rendered the
Mukaiyama–Michael a mainstay transformation in chemical synthesis.2,3 It is surprising to
consider, therefore, that α,β-unsaturated aldehydes have been largely bypassed as
electrophilic coupling partners in this venerable 1,4-addition. This deficiency in
Mukaiyama–Michael technology may arise, in part, from the documented selectivity of
Lewis acids to promote 1,2-formyl activation (Eq. 1) in preference to 1,4-olefin addition
(Eq. 2) with ambident electrophiles such as α,β-unsaturated aldehydes.4,5 Herein, we reveal
that iminium organocatalysis using chiral imidazolidinones has enabled the enantioselective
Mukaiyama–Michael reaction of simple unsaturated aldehydes with a variety of silylketene
acetals.6 Moreover, we document that the use of silylkene acetals derived from thioesters or
pyrrole amides allows selective access to syn- or anti-2,3-di-substituted, 1,5-dicarbonyl
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products respectively. This non-traditional approach to the Mukaiyama–Michael reaction
further serves to highlight the complementary nature of LUMO-lowering iminium and metal
catalysis.
(1)
(2)
2. Results and discussion
2.1. Design plan
The capacity of chiral secondary amines to catalyze the conjugate addition of a wide range
of π-nucleophiles to α,β-unsaturated aldehydes has been well established.7 We sought to
extend this mechanism of action to the addition of latent enolate equivalents such as
silylketene acetals, to provide acyclic Mukaiyama–Michael adducts with high levels of
diastereo- and enantiocontrol. Molecular modeling of the iminium ion formed from the
condensation of an α,β-unsaturated aldehyde and imidiazolidinone catalyst 1 revealed that
such a substrate should be inactive towards 1,2-addition due to non-bonding interactions
between the silyl enolate and the catalyst framework (MM3-2).8 As such, we presumed that
catalyst 1 might partition such π-nucleophiles toward a 1,4-addition manifold while
enforcing selective Si-face addition in the carbon–carbon bond-forming event. Moreover, we
hoped that such a process might evolve to be diastereoselective (anti or syn selective) via the
introduction and evaluation of various carbonyl substituents on the silyl enolate precursor.
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2.2. Optimization studies
Our enantioselective organocatalytic Mukaiyama–Michael addition was first examined
using crotonaldehyde, imidazolidinone catalyst 1 and a variety of latent enolate equivalents.
As revealed in Table 1, both O-alkyl and S-phenyl substituted silylketene acetals proved to
be inoperable nucleophiles due to competitive substrate hydrolysis using our standard
iminium catalysis conditions (Table 1, entries 1 and 2). In contrast, S-alkyl (Z)-silyl enolates
underwent rapid addition with complete 1,4-regiocontrol to furnish the desired syn-
Mukaiyama–Michael adducts in 38–70% yield, 91% ee, and up to 5.8:1 syn-selectivity
(Table 2, entries 3–6). Notably, the Si-Pr substituted silylketene thioacetal exhibited the
highest levels of reaction efficiency and selectivity, presumably due to its increased stability
towards hydrolysis as well as amplification of the steric factors that lead to enantio- and
diasterofacial control (70% conversion, 5.8:1 syn/anti, 90% ee). Unfortunately, all attempts
to further expand this trend via use of the S-tert-Butyl silylketene thioacetal led only to
significantly lower levels of conversion (38% conversion, 5.4:1 syn/anti, 88% ee). While the
use of Z-enolates derived from thioesters allowed selective formation of the corresponding
syn conjugate addition adduct, we were delighted to find that the E-silyl enolate of pyrrole
amides led to the corresponding anti isomer while maintaining useful levels of
enantiocontrol (entry 7, 1:17 anti/syn, 83% ee). Having established optimal conditions for
the generation of both syn- and anti-Mukaiyama–Michael adducts, we next focused on
defining the scope of reaction substrates for both addition protocols.
2.3. Substrate scope
The scope of the syn-Mukaiyama–Michael reaction using S-i-Pr silylketene acetals was first
explored (Table 2). As shown in Table 2, a range of electronically diverse α,β-unsaturated
aldehydes readily participate in this new 1,4-conjugate addition with useful levels of
diastereo- and enantioselectivity. For example, both electron-rich alkyl (entries 1 and 2, 62–
76% yield, 6–10:1 syn/anti, 90% ee) and electron-withdrawing methyl ester (entry 4, 73%
yield, 4:1 syn/anti 91% ee) substituents are well tolerated and give rise to highly
enantioenriched products. Moreover, the use of aryl substituted enals (cinnamaldehyde)
leads to highly syn-selective products (entry 3, 50% yield, 20:1 syn/anti, 90% ee), albeit
with moderate reaction efficiency. Variation of the silylketene thioacetal is also possible
(entries 5 and 6, R1=Et, OBn) with the α-benzyloxy nucleophile providing the syn product
exclusively with excellent enantiocontrol (82% yield, >20:1 syn/anti, 90% ee).
As revealed in Table 3, significant structural variation in the synthesis of anti-Mukaiyama–
Michael products can also be accomplished using this new iminium catalysis protocol. Once
again, α,β-unsaturated aldehydes that incorporate alkyl and aryl substituents readily couple
with (E)-1-pyrrolyl silylketene acetal with good levels of efficiency and stereoselectivity
(entries 1–3, 55–92% yield, 1:3–17 syn/anti, 83–98% ee). Notably, this conjugate addition is
successful with of a wide spectrum of substituents on the pyrrole silyl enolate component.
For example, alkyl (entries 1 and 4, R1=Me, CH2c-pentyl), benzyloxy (entry 6, R1=OBn),
and aromatic substituents (entry 5, R1=Ph) all maintain useful anti-diastereocontrol and
enantioselectivities (1:3 to >20 syn/anti, 83–93% ee). It is important to note that π-
nucleophiles of diverse reactivity are able to participate in this enantioselective conjugate
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addition without enol hydrolysis and with useful reaction efficiency if the acidity of the co-
catalyst is suitably adjusted (as described in Table 3).
The various advantages of this new organocatalytic Mukaiyama–Michael reaction should be
noted. For example, both syn and anti diastereomers can be readily accessed via the
judicious selection of silylketene acetal architecture. Moreover, the diastereoselectivity of
both the syn and anti protocols are predicted by known transition state models,2 as is the
sense of enantioinduction using the computational structure MM3-2. Additionally, all of the
reactions described herein were performed under aerobic atmosphere with wet solvents
using an inexpensive, commercial, bench stable amine catalyst.
3. Conclusions
In summary, LUMO-lowering organocatalysis has been extended to the development of a
general Mukaiyama–Michael reaction involving Z- and E-silylketene acetals with a variety
of α,β-unsaturated aldehydes. Both syn and anti 1,4-addition adducts can be obtained with
good levels of enantio- and diastereocontrol through judicious selection of the π-
nucleophile. Moreover, the conjugate addition product is observed as the sole regioisomer,
highlighting the complementary nature of organocatalysis and metal catalysis.
4. Experimental section
4.1. General
Commercial reagents were purified prior to use following the guidelines of Perrin and
Armarego.9 Organic solutions were concentrated under reduced pressure on a Büchi rotary
evaporator. Chromatographic purification of products was accomplished using forced-flow
chromatography on ICN 60 32–64 mesh silica gel 63 according to the method described by
Still.10 Thin-layer chromatography (TLC) was performed on EM Reagents 0.25 mm silica
gel 60-F plates. Visualization of the developed chromatogram was performed by
fluorescence quenching, p-anisaldehyde stain, or KMnO4 stain. 1H NMR and 13C NMR
spectra were recorded on Varian Mercury-300 (300 MHz and 75 MHz, respectively) or
Varian I-500 (500 MHz and 125 MHz, respectively) instruments, as noted, and are internally
referenced to residual protio solvent signals. Data for 1H NMR are reported with chemical
shift (δ ppm), multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet), coupling
constant (Hz), integration, and assignment. Data for 13C NMR are reported with chemical
shift. IR spectra were recorded on a Perkin Elmer Paragon 1000 FTIR and are reported in
terms of frequency of absorption (cm−1). Optical rotations were recorded on a Jasco P-1010
polarimeter (WI lamp, 589 nm, 25 °C, CHCl3). Mass spectra were obtained from the
California Institute of Technology Mass Spectrometer Facility. Gas chromatography was
performed on Agilent 5890A and Hewlett-Packard 6890 Series gas chromatographs
equipped with a split/splitless capillary injection system and flame ionization detectors using
the following columns: J&C industries DB-1701 (30 m×0.25 mm), Bodman Chiraldex Γ-TA
(30 m×0.25 mm). HPLC analysis was performed on a Hewlett-Packard 1100 Series HPLC at
254 nm using the following Chiralcel columns: OD-H (25 cm) and OD-H guard (5 cm), AD-
H (25 cm) and AD-H guard (5 cm).
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4.2. General procedure for the organocatalytic Mukaiyama–Michael reaction
A 1-dram vial with a magnetic stirrer was charged with the appropriate (2S,5S)-5-benzyl-2-
tert-butyl-3-methyl-imidazolidin-4-one salt (1), the appropriate solvent, H2O, and α,β-
unsaturated aldehyde. The solution was then stirred at room temperature for 5 min before
being cooled to the desired temperature. The solution was stirred for 5 min before the
appropriate silylketene acetal was added. The resulting mixture was maintained at the
desired temperature until consumption of the silylketene acetal as determined by TLC. The
reaction was then quenched by cold filtration through silica and purified by silica gel
chromatography.
4.3. General procedure for the preparation of acyl oxazolidinone derivatives
An analytical quantity (approximately 10 mg) of the purified Mukaiyama–Michael adduct
was oxidized to the corresponding acid according to the procedure previously described in
the literature.11 The crude acid was then coupled to 2-oxazolidinone according to the
procedure previously described in the literature.3e The resulting product was purified by
silica gel chromatography (20–35% EtOAc/Hex).
4.4. Synthesis and characterization
4.4.1. (2S,5S)-5-Benzyl-2-tert-butyl-3-methyl-imidazolidin-4-one (1)—The title
compound was prepared as previously described in the literature.12 All spectral data were in
agreement with those previously reported. [α]D −71.8 (free base).
4.4.2. tert-Butyl-1-(isopropylsulfanyl-propenyloxy)-dimethylsilane—The title
compound was prepared from thiopropionic acid S-isopropyl ester according to the
procedure described in the literature.3e Bp=43 °C (160 mT); IR (CH2Cl2) 2960, 2930, 2860,
1634, 1473, 1463,1364, 1256, 1152,1110, 946, 853, 840, 781 cm−1; 1H NMR (300 MHz,
CDCl3) δ 5.09 (q, J=6.8 Hz, 1H, vinyl), 3.30 (septet, J=6.9 Hz, 1H, SCH(CH3)2), 1.68 (d,
J=6.8 Hz, 3H, methyl), 1.26 (d, J=6.9 Hz, 6H, SCH(CH3)2), 0.93 (s, 9H, Si(CH3)2C(CH3)3),
0.17 (s, 6H, Si(CH3)2C(CH3)3); 13C NMR (75 MHz, CDCl3) δ 145.4, 110.2, 35.0, 25.9,
25.7, 23.2, 18.1, 13.7, −4.7; HRMS (FAB peg) exact mass calcd for M+H (C12H27OSiS)
requires m/z 247.1552, found m/z 247.1540.
4.4.3. tert-Butyl-(1-isopropylsulfanyl-but-1-enyloxy)-dimethylsilane—The title
compound was prepared from thiobutyric acid S-isopropyl ester according to the procedure
described in the literature.3e The title compound was purified by removing all volatiles from
the crude product by distillation (15 mT, 100 °C bath). IR (CH2Cl2) 2960, 2931, 2896, 2860,
1627, 1472, 1463, 1363, 1256, 1151, 1130, 1112, 1063, 1006, 840, 781, 675 cm−1; 1H NMR
(300 MHz, CDCl3) δ 5.06 (t, J=7.5 Hz, 1H, vinyl-H), 3.30 (septet, J=6.6 Hz, 1H,
SCH(CH3)2), 2.13 (app pentet, J=7.7 Hz, 2H, CH2CH3), 1.51 (d, J=6.9 Hz, 6H,
SCH(CH3)2), 0.96–0.90 (m, 12H, SiC(CH3)3 and CH2CH3), 0.18 (s, 6H, Si(t-Bu)
(CH3)2); 13C NMR (75 MHz, CDCl3) δ 144.4, 117.9, 34.8, 25.7, 23.2, 21.9, 18.1, 14.7,
−4.7; HRMS (EI) exact mass calcd for (C13H28OSiS) requires m/z 260.1630, found m/z
260.1625.
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4.4.4. Z-(2-Benzyloxy-1-isopropylsulfanyl-vinyloxy)-tert-butyl-dimethylsilane—
The title compound was prepared from benzyloxy-thioacetic acid S-isopropyl ester
according to the procedure described in the literature.3e The title product was isolated from
the crude reaction mixture by filtration through triethylamine-treated silica (5% TEA/
hexanes). IR (CH2Cl2) 2958, 2929, 2859, 1252, 1153, 839, 782 cm−1; 1H NMR (300 MHz,
CDCl3) δ 7.31–7.16 (m, 5H, ArH), 6.18 (s, 1H, vinyl-H), 4.70 (s, 2H, CH2Ph), 3.19 (septet,
J=6.6 Hz, 1H, SCH(CH3)2), 1.19 (d, J=6.6 Hz, 6H, SCH(CH3)2), 0.81 (s, 9H, Si(C(CH3)3)
(CH3)2), 0.01 (s, 6H, Si(C(CH3)3)(CH3)2); 13C NMR (75 MHz, CDCl3) δ 138.2, 137.4,
133.0, 128.5, 128.0, 127.9, 74.4, 35.6, 25.9, 23.4, 18.3, −4.4; HRMS (FAB) exact mass
calcd for (C18H30O2SiS) requires m/z 338.1736, found m/z 338.1747.
4.4.5. (2S,3R)-2,3-Dimethyl-5-oxo-pentanethioic acid S-isopropyl ester (Table
2, entry 1)—The title compound was prepared according to the general procedure from
crotonaldehyde (124 μL, 1.5 mmol), tert-butyl-1-(isopropylsulfanyl-propenyloxy)-
dimethylsilane (0.14 mL, 0.50 mmol), and (2S,5S)-5-benzyl-2-tert-butyl-3-methyl-
imidazolidin-4-one·TCA 1 (41 mg, 0.10 mmol) in acetone (0.25 mL) and H2O (9.0 μL, 0.50
mmol) at −78 °C for 23 h. The resulting residue was purified by silica gel chromatography
(10% ether/pentane) to provide the pure product as a colorless oil in 76% yield (77 mg, 0.38
mmol). 10:1 syn/anti. syn Isomer: IR (CH2Cl2) 2968, 1725, 1681, 1455, 1384, 1369, 1246,
965, 752 cm−1; 1H NMR (500 MHz, CDCl3) δ 9.72 (dd, J=2.5, 1.7 Hz, 1H, CHO), 3.62
(septet, J=6.9 Hz, 1H, SCH(CH3)2), 2.58–2.38 (m, 2H, CHOCH2), 2.34–2.22 (m, 1H,
COCH(CH3)C), 1.32–1.24 (m, 7H, CCH(CH3)C and SCH(CH3)2), 1.14 (d, J=6.9 Hz, 3H,
COCH(CH3)), 0.96 (d, J=6.6 Hz, 3H, CCH(CH3)C); 13C NMR (75 MHz, CDCl3) δ 203.0,
201.7, 53.1, 48.8, 34.9, 31.3, 23.3, 23.2, 17.2, 14.5; HRMS (EI) exact mass calcd for M+H
(C10H19O2S) requires m/z 203.1106, found m/z 203.1106. [α]D +34.1. Diastereomeric ratios
were determined by 1H NMR analysis. Enantiomeric excess was determined by conversion
to the corresponding acyl oxazolidinone.
4.4.6. (2S,3R)-2,3-Dimethyl-5-oxo-5-(2-oxo-oxazolidin-3-yl)-pentanethioic acid
S-isopropyl ester—The title compound was prepared according to the general procedure.
syn 90% ee. syn Isomer: IR (CH2Cl2) 2970, 1780, 1697, 1685, 1388, 1219, 965 cm−1; 1H
NMR (300 MHz, CDCl3) δ 4.04 (t, J=8.0 Hz, 2H, OCH2CH2N), 4.01 (t, J=8.2 Hz, 2H,
OCH2CH2N), 3.61 (septet, J=6.9 Hz, 1H, SCH(CH3)2), 3.16–2.36 (m, 4H, COCH2CH-
(CH3)CH(CH3)CO), 1.29 (d, J=1.9 Hz, 3H, SCH(CH3)(CH3)), 1.27 (d, J=1.9 Hz, 3H,
SCH(CH3)(CH3)), 1.12 (d, J=7.2 Hz, 3H, COCH(CH3)C), 0.95 (d, J=6.9 Hz, 3H,
COCH2CH(CH3)C); 13C NMR (75 MHz, CDCl3) δ 203.2, 172.3, 153.7, 62.2, 52.4, 42.7,
39.9, 34.7, 34.5, 32.4, 23.2, 16.2, 13.1; HRMS (FAB) exact mass calcd for (C13H22NO4S)
requires m/z 288.1270, found m/z 288.1264. [α]D +37.1. Enantiomeric excess was
determined by HPLC analysis (OD-H and OD-H guard, 3% isopropanol in hexanes, 1 mL/
min); (2R,3S) isomer tR=89.3 min and (2S,3R) isomer tR=100.0 min.
4.4.7. (2S,3R)-2-Methyl-3-(2-oxo-ethyl)hexanethioic acid S-isopropyl ester
(Table 2, entry 2)—The title compound was prepared according to the general procedure
from 2-hexenal (157 μL, 1.35 mmol), tert-butyl-1-(isopropylsulfanyl-propenyloxy)-
dimethylsilane (0.13 mL, 0.45 mmol), and (2S,5S)-5-benzyl-2-tert-butyl-3-methyl-
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imidazolidin-4-one·TCA 1 (37 mg, 0.090 mmol) in acetone (0.225 mL) and H2O (8.1 μL,
0.45 mmol) at −78 °C for 22 h. The resulting residue was purified by silica gel
chromatography (3% EtOAc/Hex) to provide the pure product as a colorless oil in 62% yield
(64 mg, 0.28 mmol). 6:1 syn/anti. syn Isomer: IR (CH2Cl2) 2961, 2931, 1725, 1680, 1463,
1367, 965 cm−1; 1H NMR (500 MHz, CDCl3) δ 9.74 (t, J=2.0 Hz, 1H, CHO), 3.62 (septet,
J=6.8 Hz, 1H, SCH(CH3)2), 2.72–2.64 (m, 1H, COCH(CH3)C), 2.52 (ddd, J=17.1, 5.4, 2.0
Hz, 1H, CHHCHO), 2.43–2.32 (m, 2H, CH(n-Pr)CHHCHO), 1.43–1.22 (m, 10H), 1.14 (d,
J=6.8 Hz, 3H, COCH(CH3)C), 0.89 (t, J=6.8 Hz, 3H, CH2CH3); 13C NMR (75 MHz,
CDCl3) δ 203.0, 202.1, 51.0, 46.2, 36.1, 34.9, 33.8, 23.3, 23.1, 20.1, 14.9, 14.5; HRMS (EI)
exact mass calcd for (C12H22O2S) requires m/z 230.1341, found m/z 230.1341. [α]D +29.5.
Diastereomeric ratios were determined by 1H NMR analysis. Enantiomeric excess was
determined by conversion to the corresponding acyl oxazolidinone.
4.4.8. (2S,3R)-2-Methyl-3-[2-oxo-2-(2-oxo-oxazolidin-3-yl)-ethyl]-hexanethioic
acid S-isopropyl ester—The title compound was prepared according to the general
procedure. syn 90% ee. syn Isomer: IR (CH2Cl2) 2962, 1782, 1697, 1684, 1387, 1223, 1197,
958 cm−1; 1H NMR (300 MHz, CDCl3) δ 4.40 (t, J=7.2 Hz, 2H, OCH2CH2N), 4.02 (t, J=7.7
Hz, 2H, OCH2CH2N), 3.61 (septet, J=6.9 Hz, 1H, SCH(CH3)2), 3.12–2.70 (m, 3H
COCH2CH(n-Pr)CH(CH3)CO), 2.52–2.40 (m, 1H, CCH(n-Pr)C), 1.40–1.20 (m, 10H,
SCH(CH3)2 and CH2CH2CH3),1.11 (d, J=6.9 Hz, 3H, CH(CH3)CO), 0.87 (t, J=6.6 Hz, 3H,
CH2CH3); 13C NMR (75 MHz, CDCl3) δ 203.2, 172.8, 153.7, 62.2, 50.6, 42.8, 37.1, 37.0,
34.6, 32.9, 23.3, 23.1, 20.3, 14.4, 13.1; HRMS (FAB) exact mass calcd for (C15H26NO4S)
requires m/z 316.1583, found m/z 316.1581. [α]D +30.3. Enantiomeric excess was
determined by HPLC analysis (AD-H and AD-H guard, 3% isopropanol in hexanes, 1 mL/
min); (2S,3R) isomer tR=25.3 min and (2R,3S) isomer tR=27.0 min; anti diastereomers
tR=30.2 and 33.5 min.
4.4.9. (2S,3R)-2-Methyl-5-oxo-3-phenyl-pentanethioic acid S-isopropyl ester
(Table 2, entry 3)—The title compound was prepared according to the general procedure
from cinnamaldehyde (76 μL, 0.60 mmol), tert-butyl-1-(isopropylsulfanyl-propenyloxy)-
dimethylsilane (95 μL, 0.40 mmol), and (2S,5S)-5-benzyl-2-tert-butyl-3-methyl-
imidazolidin-4-one·TCA 1 (33 mg, 0.080 mmol) in acetone (0.20 mL), cyclohexane (14 μL),
and H2O (9.0 μL, 0.50 mmol) at −78 °C for 24 h. The resulting residue was purified by silica
gel chromatography (5% EtOAc/Hex) to provide the pure product as a colorless oil in 50%
yield (52 mg, 0.20 mmol). 20:1 syn/anti. syn Isomer: IR (CH2Cl2) 2967, 1725, 1677, 1453,
963, 702 cm−1; 1H NMR (300 MHz, CDCl3) δ 9.51 (t, J=2.2 Hz, 1H, CHO), 7.34–7.14 (m,
5H, ArH), 3.67 (septet, J=6.6 Hz, 1H, SCH(CH3)2), 3.44 (dt, J=10.4, 7.1 Hz, 1H CHPh),
2.86–2.78 (m, 1H, COCH(CH3)C), 2.77 (dd, J=7.1, 1.7 Hz, 2H, CHOCH2), 1.33 (d, J=6.7
Hz, 3H, SCH(CH3)(CH3)), 1.31 (d, J=6.0 Hz, 3H, SCH(CH3)(CH3)), 0.95 (d, J=6.6 Hz, 3H,
CH3); 13C NMR (75 MHz, CDCl3) δ 203.0, 200.8, 140.8, 128.9, 128.2, 127.4, 54.0, 48.3,
43.6, 35.1, 23.3, 23.2, 17.2; HRMS (EI) exact mass calcd for (C15H20O2S) requires m/z
264.1184, found m/z 264.1182. [α]D +49.6. Diastereomeric ratios were determined by GLC
analysis (Γ-TA column, 130 °C isotherm, 1 mL/min); syn diastereomer tR= 33.1 min and
anti diastereomer tR=36.6 min. Enantiomeric excess was determined by conversion to the
corresponding acyl oxazolidinone.
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4.4.10. (2S,3R)-2-Methyl-5-oxo-5-(2-oxo-oxazolidin-3-yl)-3-phenyl-
pentanethioic acid S-isopropyl ester—The title compound was prepared according to
the general procedure. syn 90% ee. syn Isomer: IR (CH2Cl2) 2968, 2929, 1780, 1699, 1678,
1455, 1388, 1272, 1224, 1041, 968, 760, 702 cm−1; 1H NMR (300 MHz, CDCl3) δ 7.32 (m,
5H, ArH), 4.35–4.15 (m, 2H, OCH2CH2N), 3.95–3.45 (m, 5H), 3.10 (app dd, J=16.2, 3.0
Hz, 1H, COCHHCH(Ph)), 2.88 (ddd, J=17.1, 9.9, 7.2 Hz, 1H, COCHHCH(Ph)), 1.33 (d,
J=6.9 Hz, 3H, SCH(CH3)(CH3)), 1.30 (d, J=7.2 Hz, 3H, SCH(CH3)(CH3)), 0.93 (d, J=6.9
Hz, 3H, COCH(CH3)C); 13C NMR (75 MHz, CDCl3) δ 203.0, 171.2, 153.4, 141.2, 128.4,
128.3, 126.9, 61.9, 53.3, 44.4, 42.4, 39.4, 34.7, 23.0, 22.9, 17.0; HRMS (FAB) exact mass
calcd for M+H (C18H24NO4S) requires m/z 350.1426, found m/z 350.1421. [α]D +34.7.
Enantiomeric excess was determined by HPLC analysis (OD-H and OD-H guard, 6%
isopropanol in hexanes, 1 mL/min); (2S,3R) isomer tR=47.6 min and (2R,3S) isomer tR=54.3
min.
4.4.11. (2S,3R)-5-((4S)-4-Benzyl-2-oxo-oxazolidin-3-yl)-2-methyl-5-oxo-3-
phenyl-pentanethioic acid S-isopropyl ester—The title compound was prepared
according to the general procedure. IR (CH2Cl2) 2971, 2928, 1782, 1702, 1674, 1454, 1388,
1355, 1213, 954, 761, 739, 702 cm−1; 1H NMR (300 MHz, CDCl3) δ 7.26–7.03 (m, 10H,
ArH), 4.38–4.26 (m, 1H, OCH2CH(Bn)N), 3.95 (dd, J=9.0, 2.7 Hz, OCHHCH(Bn)N), 3.90–
3.36 (m, 4H), 3.13–3.00 (m, 2H, CH2Ph), 2.90–2.76 (m, 1H, COCHHCH(Ph)), 2.55 (dd,
J=13.4, 9.8 Hz, 1H, COCHHCH(Ph)), 1.29 (d, J=6.9 Hz, 3H, SCH(CH3)(CH3)), 1.25 (d,
J=6.9 Hz, 3H, SCH(CH3)(CH3)), 0.88 (d, J=6.9 Hz, 3H, COCH(CH3)C); 13C NMR (75
MHz, CDCl3) δ 203.0, 171.1, 153.3, 141.1, 135.3, 129.4, 128.9, 128.5, 128.4, 127.2, 127.0,
66.0, 55.1, 53.5, 44.7, 39.7, 37.7, 34.7, 31.2, 23.0, 22.9, 17.0; HRMS (FAB) exact mass
calcd for M+H (C25H30NO4S) requires m/z 440.1896, found m/z 440.1882. [α]D +64.5. The
title compound was recrystallized (THF/hexanes) to afford X-ray quality crystals for XRD
analysis (see supplementary data).
4.4.12. (2S,3R)-3-Isopropylsulfanylcarbonyl-2-(2-oxo-ethyl)-butyric acid methyl
ester (Table 2, entry 4)—The title compound was prepared according to the general
procedure from 4-oxo-but-2-enoic acid methyl ester (43 mg, 0.38 mmol), tert-butyl-1-
(isopropylsulfanyl-propenyloxy)-dimethylsilane (59 μL, 0.25 mmol), and (2S,5S)-5-
benzyl-2-tert-butyl-3-methyl-imidazolidin-4-one·TCA 1 (20 mg, 0.050 mmol) in acetone
(0.125 mL) and H2O (4.5 μL, 0.25 mmol) at −78 °C for 22 h. The resulting residue was
purified by silica gel chromatography (CH2Cl2) to provide the pure product as a colorless oil
in 73% yield (45 mg, 0.18 mmol). 4:1 syn/anti. syn 91% ee. syn Isomer: 1H NMR (300
MHz, CDCl3) δ 9.73 (app s, 1H, CHO), 3.71 (s, 3H, CO2CH3), 3.64 (septet, J=6.9 Hz, 1H,
SCH(CH3)2), 3.19 (qd, J=7.7, 3.7 Hz, 1H COCH (CH3)C), 3.01–2.87 (m, 2H, COCH2C),
2.64 (td, J=3.2, 0.5 Hz, 1H, (CH2)(CH)CHCO2CH3), 2.60 (d, J=6.9 Hz, 6H, SCH(CH3)2),
1.20 (d, J=6.9 Hz, 3H, COCH(CH3)C); 13C NMR (75 MHz, CDCl3) δ 201.1, 199.4, 173.3,
52.1, 48.2, 43.2, 41.0, 34.9, 22.9, 22.8, 15.8; HRMS (EI) exact mass calcd for M+H
(C11H19O4S) requires m/z 247.1004, found m/z 247.1015. [α]D +0.74. Diastereomeric ratios
and enantiomeric excess were determined by GLC analysis (Γ-TA column, 130 °C isotherm,
1 mL/min); (2S,3R) isomer tR=29.1 min, (2R,3S) isomer tR= 30.4 min, and anti isomer
tR=33.0 min.
Borths et al. Page 8
Tetrahedron. Author manuscript; available in PMC 2014 September 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4.4.13. (2S,3R)-2-Ethyl-3-methyl-5-oxo-pentanethioic acid S-isopropyl ester
(Table 2, entry 5)—The title compound was prepared according to the general procedure
from crotonaldehyde (25 μL, 0.30 mmol), tert-butyl-(1-isopropylsulfanyl-but-1-enyloxy)-
dimethylsilane (29 μL, 0.10 mmol), and (2S,5S)-5-benzyl-2-tert-butyl-3-methyl-
imidazolidin-4-one·TCA 1 (8.0 mg, 0.020 mmol) in diethyl ether (0.050 mL), benzyl methyl
ether (5.0 μL), and H2O (1.8 μL, 0.10 mmol) at −78 °C. The solution was stirred until the
reaction was judged to be complete by GLC analysis (DB-1701 column, 70 °C, 25 °C/min
gradient, 1 mL/min); benzyl methyl ether tR=3.75 min, 2-ethyl-3-methyl-5-oxo-
pentanethioic acid S-isopropyl ester tR=6.40 min. A yield of 76% was determined by
comparison of the peak areas of benzyl methyl ether and 2-ethyl-3-methyl-5-oxo-
pentanethioic acid S-isopropyl ester.4:1 syn/anti. syn Isomer: IR (CH2Cl2) 2968, 1727, 1678,
1461, 990, 833 cm−1; 1H NMR (300 MHz, CDCl3) δ 9.72 (dd, J=2.4, 1.3 Hz, 1H, CHO),
3.66 (septet, J=6.9 Hz, 1H, SCH(CH3)2), 2.62–2.20 (m, 3H,
CHOCH2CH(CH3)CH(Et)COS(i-Pr)), 1.77–1.46 (m, 3H, CH2CH(CH3)C and CH2CH3),
1.30 (d, J=6.9 Hz, 6H, SCH(CH3)2), 0.99 (d, J=6.1 Hz, 3H, CH2CH(CH3)C), 0.91 (t, J=7.5
Hz, 3H, CH2CH3); 13C NMR (75 MHz, CDCl3) δ 202.6, 201.8, 60.5, 48.3, 48.2, 34.7, 30.3,
23.0, 22.9, 17.9, 11.8; HRMS (EI) exact mass calcd for M−H (C11H19O2S) requires m/z
215.1106, found m/z 215.1114. [α]D +2.0. Di-astereomeric ratios were determined by 1H
NMR analysis. Enantiomeric excess was determined by conversion to the corresponding
acyl oxazolidinone.
4.4.14. (2S,3R)-2-Ethyl-3-methyl-5-oxo-5-(2-oxo-oxazolidin-3-yl)-pentanethioic
acid S-isopropyl ester—The title compound was prepared according to the general
procedure. syn 94% ee. syn Isomer: IR (CH2Cl2) 2966, 1779, 1682, 1456, 1386, 1223, 1109,
1042, 990, 827, 761, 707 cm−1; 1H NMR (300 MHz, CDCl3) δ 4.41 (t, J=8.2 Hz, 2H,
OCH2CH2N), 4.02 (t, J=7.4 Hz, 2H, OCH2CH2N), 3.65 (septet, J=6.9 Hz, 1H, SCH(CH3)2),
3.03–2.85 (m, 1H, CHCOS(i-Pr)), 2.53–2.36 (m, 2H, COCH2), 1.80–1.40 (m, 4H),1.29 (d,
J=6.9 Hz, 6H, SCH(CH3)2), 0.99 (d, J=6.6 Hz, 3H, CHCH3), 0.90 (t, J=7.2 Hz, 3H,
CH2CH3); 13C NMR (75 MHz, CDCl3) δ 202.5, 172.3, 153.4, 62.0, 60.0, 42.5, 39.6, 34.6,
31.8, 26.3, 22.9, 21.8, 17.1, 12.0; HRMS (EI) exact mass calcd for M+H (C14H24NO4S)
requires m/z 302.1426, found m/z 302.1440. [α]D +20.7. Enantiomeric excess was
determined by HPLC analysis (OD-H and OD-H guard,1% ethanol in hexanes, 1 mL/min);
syn isomers tR=54.2 and 68.4 min and anti isomers tR=48.6 and 49.8 min.
4.4.15. (2S,3R)-2-Benzyloxy-3-methyl-5-oxo-pentanethioic acid S-isopropyl
ester (Table 2, entry 6)—The title compound was prepared according to the general
procedure from crotonaldehyde (85 μL, 1.0 mmol), Z-(2-benzyloxy-1-isopropylsulfanyl-
vinyloxy)-tert-butyl-dimethylsilane (0.12 mL, 0.34 mmol), and (2S,5S)-5-benzyl-2-tert-
butyl-3-methyl-imidazolidin-4-one·TFA 1 (25 mg, 0.068 mmol) in CH2Cl2 (0.17 mL) and
H2O (6.1 μL, 0.34 mmol) at −78 °C for 24 h. The resulting residue was purified by silica gel
chromatography (10% EtOAc/Hex) to provide the pure product as a colorless oil in 82%
yield (82 mg, 0.28 mmol). >20:1 syn/anti. syn Isomer: IR (CH2Cl2) 2966, 1724,1676, 1456,
1124, 1087, 1059, 738, 699 cm−1; 1H NMR (300 MHz, CDCl3) δ 9.62 (t, J=2.2 Hz, 1H,
CHO), 7.40–7.28 (m, 5H, ArH), 4.81 (d, J=11.5 Hz, 1H, PhCHHO), 4.35 (d, J=11.5 Hz, 1H,
PhCHHO), 3.86 (d, J=4.4 Hz, 1H, COCH(OBn)C), 3.65, (septet, J=7.1 Hz, 1H,
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SCH(CH3)2), 2.66–2.45 (m, 2H, CHOCHHCH(CH3)C), 2.31 (ddd, J=16.5, 6.6, 1.6 Hz, 1H,
CHOCHHC), 1.34 (d, J=3.3 Hz, 3H, SCH(CH3)(CH3)), 1.32 (d, J=3.3 Hz, 3H, SCH(CH3)
(CH3)), 0.98 (d, J=7.1 Hz, 3H, CHOCH2CH(CH3)C); 13C NMR (75 MHz, CDCl3) δ 202.7,
201.2, 137.1, 128.6, 128.4, 128.2, 86.8, 73.9, 47.4, 32.3, 25.9, 23.3, 23.2, 15.0; HRMS
(FAB) exact mass calcd for M+H (C16H23O3S) requires m/z 295.1368, found m/z 295.1376.
[α]D +77.1. Diastereomeric ratios were determined by 1H NMR or GLC analysis (DB-1701
column, 70 °C, 25 °C/min gradient to 280 °C isotherm, constant flow 1 mL/min); syn Isomer
tR=9.02 min and anti isomer tR=9.38 min. Enantiomeric excess was determined by
conversion to the corresponding acyl oxazolidinone.
4.4.16. (2S,3R)-2-Benzyloxy-3-methyl-5-oxo-5-(2-oxo-oxazolidin-3-yl)-
pentanthioic acid S-isopropyl ester—The title compound was prepared according to
the general procedure. syn 90% ee. syn Isomer: IR (CH2Cl2) 2968, 2929, 2869, 1782, 1697,
1677, 1479, 1455, 1388, 1312, 1223, 1102, 1042, 755, 701 cm−1; 1H NMR (300 MHz,
CDCl3) δ 7.41–7.25 (m, 5H, ArH), 4.86 (d, J=11.5 Hz, 1H, OCHHCH2N), 4.35 (d, J=8.2
Hz, 2H, CH2Ph), 4.32 (d, J=5.0 Hz,1H, OCHHCH2N), 4.00 (d, J=3.9 Hz,1H,
COCH(OBn)C), 3.97–3.71 (m, 2H, OCH2CH2N), 3.65 (septet, J=7.1 Hz, 1H, SCH(Me)2),
2.94 (dd, J=17.6, 8.2 Hz, 1H, COCHHC), 2.79 (dd, J=17.6, 5.5 Hz, 1H, COCHHC), 2.63–
2.52 (m, 1H, CHMe), 1.34 (d, J=2.2 Hz, 3H, SCH(CH3)(CH3)), 1.32 (d, J=2.8 Hz, 3H,
SCH(CH3)(CH3)), 0.98 (d, J=7.1 Hz, 3H, CH(CH3)); 13C NMR (75 MHz, CDCl3) δ 203.2,
171.8, 155.5, 137.5, 128.7, 128.5, 127.9, 85.9, 73.9, 62.1, 42.5, 38.5, 34.1, 33.4, 23.3,
23.3,14.6; HRMS(EI) exact mass calcd for (C19H27NO5S) requires m/z 380.1532, found m/z
380.1537. [α]D +63.6. Enantiomeric excess was determined by HPLC analysis (AD-H and
AD-H guard, 10% isopropanol in hexanes, 1 mL/min); syn Isomers tR=25.1 and 31.9 min.
4.4.17. 1-(1-Trimethylsilanyloxy-propenyl)-1H-pyrrole—The title compound was
prepared as described in the literature.13 All spectral data were in agreement with those
previously reported.
4.4.18. 1-(2-Benzyloxy-1-trimethylsilanyloxy-vinyl)-1H-pyrrole—The title
compound was prepared as described in the literature.3e All spectra data were in agreement
with those previously reported.
4.4.19. 3-Cyclopentyl-1-pyrrol-1-yl-propan-1-one—The title compound was prepared
from pyrrole and 3-cyclo-pentyl-propionyl chloride according to the procedure described in
the literature.13 Analytical data. Bp=125–130 °C (2 mm Hg); IR (CH2Cl2) 2948, 2866,
1717, 1469, 1331, 1277, 1118, 1071, 921, 740 cm−1; 1H NMR (300 MHz, CDCl3) δ 7.32 (t,
J=2.2 Hz, 2H, ArH), 6.28 (t, J=2.2 Hz, 2H, ArH), 2.82 (dd J=8.5, 7.4 Hz, 2H, COCH2),
1.90–1.40 (m, 9H), 1.25–1.05 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 170.8, 119.0, 113.0,
39.6, 33.9, 32.5, 32.4, 30.9, 25.6, 25.2; HRMS (EI) exact mass calcd for (C12H27NO)
requires m/z 191.1310, found m/z 191.1310.
4.4.20. 1-(3-Cyclopentyl-1-trimethylsilanyloxy-propenyl)-1H-pyrrole—The title
compound was prepared from 3-cyclopentyl-1-pyrrol-1-yl-propan-1-one according to the
procedure described in the literature.13 IR (CH2Cl2) 2953, 2869, 1723, 1682, 1470, 1312,
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1254, 1200, 1087, 921, 847, 801, 725 cm−1; 1H NMR (300 MHz, CDCl3) δ 6.98 (t, J=2.4
Hz, 2H, ArH), 6.17 (t, J=2.4 Hz, 2H, ArH), 4.71 (t, J=7.4 Hz, 1H, vinyl), 2.88–2.62 (m, 1H),
2.49–2.31 (m, 1H), 1.95–1.35 (m, 7H), 1.30–1.00 (m, 2H), 0.35 (s, 9H, TMS); 13C NMR (75
MHz, CDCl3) δ 120.7, 119.0, 108.8, 107.5, 40.2, 32.9, 32.7, 32.4, 25.2, 25.0, 2.1; HRMS
(EI) exact mass calcd for M+H (C15H26NOSi) requires m/z 264.1784, found m/z 264.1772.
4.4.21. 1-(2-Phenyl-1-trimethylsilanyloxy-vinyl)-1H-pyrrole—The title compound
was prepared as described in the literature.3e All spectral data were in agreement with those
previously reported.
4.4.22. (3R,4R)-Dimethyl-5-oxo-5-pyrrol-1-yl-pentanal (Table 3, entry 1)—The
title compound was prepared according to the general procedure from crotonaldehyde (124
μL, 1.5 mmol), 1-(1-trimethyl-silanyloxy-propenyl)-1H-pyrrole (0.104 mL, 0.50 mmol), and
(2S,5S)-5-benzyl-2-tert-butyl-3-methyl-imidazolidin-4-one·TCA 1 (41 mg, 0.10 mmol) in
toluene (1.0 mL) and H2O (9.0 μL, 0.50 mmol) at −78 °C for 21 h. The resulting residue was
purified by silica gel chromatography (30% ether/pentane) to provide the pure product as an
oil in 92% yield (89 mg, 0.46 mmol). 1:17 syn/anti. anti isomer: IR (CH2Cl2) 2971, 1717,
1468, 1369, 1272, 1104, 1074, 909, 744 cm−1; 1H NMR (300 MHz, CDCl3) δ 9.72 (dd,
J=2.4, 1.1 Hz, 1H, CHO), 7.30 (t, J=2.4 Hz, 2H, ArH), 6.29 (t, J=2.1 Hz, 2H, ArH), 3.13
(app pentet, J=6.4 Hz, 1H, COCH(CH3)C), 2.69–2.48 (m, 2H, CHOCHHCH(CH3)C), 2.31
(ddd, J=16.8, 8.2, 2.1 Hz, 1H, CHOCHHC), 1.23 (d, J=6.9 Hz, 3H, COCH(CH3)), 1.08 (d,
J=6.9 Hz, 3H, CCH(CH3)C); 13C NMR (75 MHz, CDCl3) δ 201.3, 173.3, 119.0, 113.3,
46.7, 42.4, 30.8, 18.5, 14.1; HRMS (EI) exact mass calcd for (C11H15NO2) requires m/z
193.1103, found m/z 193.1101. [α]D −36.6. Diastereomeric ratios were determined by 1H
NMR analysis. Enantiomeric excess was determined by conversion to the corresponding
acyl oxazolidinone.
4.4.23. (2R,3R)-2,3-Dimethyl-5-(2-oxo-oxazolidin-3-yl)-1-pyrrol-1-yl-
pentane-1,5-dione—The title compound was prepared according to the general
procedure. anti 83% ee. All spectral data were consistent with those reported in the
literature.3e
4.4.24. (3R)-3-((1R)-1-Methyl-2-oxo-2-pyrrol-1-yl-ethyl)-hexanal (Table 3, entry
2)—The title compound was prepared according to the general procedure from 2-
hexenal(157 μL,1.35 mmol),1-(1-trimethylsilanyloxy-propenyl)-1H-pyrrole (94 μL, 0.45
mmol), and (2S,5S)-5-benzyl-2-tert-butyl-3-methyl-imidazolidin-4-one·DNBA 1 (41 mg,
0.090 mmol) in DME (0.225 mL) and H2O (8.1 μL, 0.45 mmol) at −40 °C for 24 h. The
resulting residue was purified by silica gel chromatography (10% EtOAc/Hex) to provide
the pure product as an oil in 56% yield (55 mg, 0.25 mmol). 1:4 syn/anti. anti isomer: IR
(CH2Cl2) 2959, 1715, 1469, 1273, 1103, 1073, 910, 744 cm−1; 1H NMR (300 MHz, CDCl3)
δ 9.81 (t, J=1.3 Hz, 1H, CHO), 7.46 (t, J=2.4 Hz, 2H, ArH), 6.31 (t, J=2.4 Hz, 2H, ArH),
3.33 (septet, J=5.3 Hz, 1H, SCH(CH3)2), 2.71–2.32 (m, 4H, CHOCH2CH(n-Pr)CH(CH3)),
1.46–1.10 (m, 7H, CH2CH2CH3 and CHCH3), 0.85 (t, J=6.9 Hz, 3H, CH2CH3); 13C NMR
(75 MHz, CDCl3) δ 201.8, 173.5, 119.3, 113.2, 45.8, 40.4, 35.1, 32.1, 20.1,14.0,13.2;
HRMS (EI) exact mass calcd for (C13H19NO2) requires m/z 221.1416, found m/z 221.1419.
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[α]D +0.42. Diastereomeric ratios were determined by 1H NMR analysis. Enantiomeric
excess was determined by conversion to the corresponding acyl oxazolidinone.
4.4.25. (2R,3R)-2-Methyl-5-(2-oxo-oxazolidin-3-yl)-3-propyl-1-pyrrol-1-yl-
pentane-1,5-dione—The title compound was prepared according to the general
procedure. anti 93% ee. anti isomer: IR (CH2Cl2) 2959, 1785, 1700, 1685, 1467, 1391,
1334, 1311, 1265, 1225, 1119, 1100, 1046 cm−1; 1H NMR (300 MHz, CDCl3) δ 7.57 (dd,
J=2.6, 2.2 Hz, 2H, ArH), 6.30 (dd, J=2.6, 2.2 Hz, 2H, ArH), 4.43 (t, J=8.4 Hz, 2H,
OCH2CH2N), 4.03 (t, J=8.4 Hz, 2H, OCH2CH2N), 3.43 (qd, J=6.6, 4.4 Hz, 1H,
COCH(Me)C), 3.13 (dd, J=18.5, 9.2 Hz, 1H, COCHHC), 3.00 (dd, J=18.0, 4.4 Hz, 1H,
COCHHC), 2.55–2.43 (m, 1H, CCCH(n-Pr)), 1.47–1.21 (m, 4H, CH2CH2CH3), 1.18 (d,
J=7.0 Hz, 3H, CHCH3), 0.82 (t, J=6.6 Hz, 3H, CH2CH3); 13C NMR (75 MHz, CDCl3) δ
173.7, 173.0, 153.7, 119.7, 113.2, 62.3, 42.8, 40.6, 37.0, 36.6, 31.5, 20.5, 14.2, 11.7; HRMS
(FAB) exact mass calcd for (C16H23N2O4) requires m/z 307.1658, found m/z 307.1653; [α]D
−18.5. Enantiomeric excess was determined by HPLC analysis (AD-H and AD-H guard, 6%
isopropanol in hexanes, 1 mL/min); (2S,3S) isomer tR=38.6 min and (2R,3R) isomer tR=41.6
min; syn Isomers tR=29.4 and 35.4 min.
4.4.26. 3-(4-Chlorophenyl)-propenal—The title compound was prepared as described
in the literature.14 All spectral data were in agreement with those previously reported.
4.4.27. (3R,4R)-3-(4-Chlorophenyl)-4-methyl-5-oxo-5-pyrrol-1-yl-pentanal
(Table 3, entry 3)—The title compound was prepared according to the general procedure
from 3-(4-chlorophenyl)-propenal (117 mg, 0.70 mmol), 1-(1-trimethylsilanyloxy-
propenyl)-1H-pyrrole (73 μL, 0.35 mmol), and (2S,5S)-5-benzyl-2-tert-butyl-3-methyl-
imidazolidin-4-one·TFA 1 (25 mg, 0.070 mmol) in THF (0.70 mL), cyclohexane (49 μL),
and H2O (6.3 μL, 0.35 mmol) at −60 °C for 23 h. The resulting residue was purified by silica
gel chromatography (20% EtOAc/Hex) to provide the pure product as an oil in 74% yield
(75 mg, 0.26 mmol). 1:3 syn/anti. anti isomer: IR (CH2Cl2) 1718, 1492, 1468, 1411, 1368,
1325, 1298, 1271, 1111, 1092, 1074, 1014, 917, 894, 827, 745 cm−1; 1H NMR (300 MHz,
CDCl3) δ 9.57 (t, J=1.8 Hz, 1H, CHO), 7.36 (br s, 2H, ArH), 7.30 (d, J=8.5 Hz, 2H, ArH),
7.14 (d, J=8.5 Hz, 2H, ArH), 6.34 (t, J=2.1 Hz, 2H, ArH), 3.66 (td, J=9.1, 5.3 Hz, 1H,
CHAr), 3.42–3.32 (m, 1H, CHCONR2), 2.89–2.71 (m, 2H, CH2CHO), 1.33 (d, J=7.0 Hz,
3H, CH3); 13C NMR (75 MHz, CDCl3) δ 199.9, 172.9, 138.8, 133.2, 129.5, 129.0, 119.0,
113.8, 47.7, 43.3, 42.2, 16.7; HRMS (EI) exact mass calcd for (C16H17NO2Cl) requires m/z
290.0948, found m/z 290.0951; [α]D −28.0. Diastereomeric ratios were determined by 1H
NMR analysis. Enantiomeric excess was determined by conversion to the corresponding
acyl oxazolidinone. syn Isomer: IR (CH2Cl2) 2976, 1720, 1710, 1492, 1467, 1409, 1366,
1323, 1275, 1094, 1074, 1014, 743 cm−1; 1H NMR (300 MHz, CDCl3) δ 9.62 (dd, J=2.1, 1.2
Hz, 1H, CHO), 7.26–7.13 (m, 6H, ArH), 6.25 (t, J=2.4 Hz, 2H, ArH), 3.74 (ddd, J=9.7, 8.2,
5.0 Hz, 1H, CHAr), 3.43 (dt, J=15.2, 7.0 Hz, 1H, CHCONR2), 2.98 (ddd, J=17.3, 4.7, 1.2
Hz, 1H, CHHCHO), 2.85 (ddd, J=17.3, 9.7, 2.1 Hz, 1H, CHHCHO), 1.33 (d, J=7.0 Hz, 3H,
CH3); 13C NMR (75 MHz, CDCl3) δ 200.4, 172.7, 140.1, 133.3, 129.5, 129.2, 119.1, 113.8,
45.7, 43.9, 41.7, 15.6; HRMS (EI) exact mass calcd for (C16H17NO2Cl) requires m/z
290.0948, found m/z 290.0945.
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4.4.28. (2R,3R)-3-(4-Chloro-phenyl)-2-methyl-5-(2-oxo-oxazolidin-3-yl)-1-
pyrrol-1-yl-pentane-1,5-dione—The title compound was prepared according to the
general procedure. anti 98% ee. anti isomer: IR (CH2Cl2) 1777, 1703, 1468, 1389, 1271,
1225, 1092, 745 cm−1; 1H NMR (300 MHz, CDCl3) δ 7.39 (t, J=2.1 Hz, 2H, ArH), 7.29 (d,
J=8.4 Hz, 2H, ArH), 7.19 (d, J=8.4 Hz, 2H, ArH), 6.34 (t, J=2.1 Hz, 2H, ArH), 4.31 (t,
J=8.4 Hz, 2H, OCH2CH2), 3.94–3.72 (m, 3H, CH2CH2N and CHAr), 3.57–3.37 (m, 2H,
COCH(CH3)C and COCHHC), 3.16 (dd, J=17.3, 5.1 Hz, 1H, COCHHC), 1.06 (d, J=7.2 Hz,
3H, CH3); 13C NMR (75 MHz, CDCl3) δ 173.0, 170.9, 153.5, 139.3, 132.9, 129.8, 128.8,
119.1, 113.7, 62.1, 43.3, 43.0, 42.2, 39.5, 16.8; HRMS (FAB) exact mass calcd for M+H
(C19H20N2O4Cl) requires m/z 375.1112, found m/z 375.1110. [α]D −12.4. Enantiomeric
excess was determined by HPLC analysis (OD-H and OD-H guard, 15% isopropanol in
hexanes, 1 mL/min); (2R,3R) isomer tR=30.4 min and (2S,2S) isomer tR=34.7 min.
4.4.29. (3R,4R)-4-Cyclopentylmethyl-3-methyl-5-oxo-5-pyrrol-1-yl-pentanal
(Table 3, entry 4)—The title compound was prepared according to the general procedure
from crotonaldehyde (99 μL, 1.2 mmol), 1-(3-cyclopentyl-1-trimethylsilanyloxy-
propenyl)-1H-pyrrole (0.11 mL, 0.40 mmol), and (2S,5S)-5-benzyl-2-tert-butyl-3-methyl-
imidazolidin-4-one·TBA 1 (43 mg, 0.080 mmol) in CH2Cl2 (0.10 mL), toluene (0.10 mL),
and H2O (7.2 μL, 0.40 mmol) at −78 °C for 24 h. The resulting residue was purified by silica
gel chromatography (10% EtOAc/Hex) to provide the pure product as a yellow oil in 68%
yield (71 mg, 0.27 mmol). 1:10 syn/anti. anti isomer: IR (CH2Cl2) 2951, 1709, 1467, 1273,
1073, 744 cm−1; 1H NMR (300 MHz, CDCl3) δ 9.71 (t, J=1.5 Hz, 1H, CHO), 7.34 (br s, 2H,
ArH), 6.35–6.15 (m, 2H ArH), 3.34–2.92 (m, 1H), 2.7–1.8 (m, 3H), 1.78–1.36 (m, 9H),
1.16–0.85 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 201.4, 173.2, 119.1, 113.5, 47.4, 47.3,
38.2, 35.5, 33.3, 33.1, 32.3, 31.0, 25.1, 18.0; HRMS (EI) exact mass calcd for (C16H23NO2)
requires m/z 261.1729, found m/z 261.1724. [α]D −14.8. Diastereomeric ratios were
determined by 1H NMR analysis. Enantiomeric excess was determined by conversion to the
corresponding acyl oxazolidinone.
4.4.30. (2R,3R)-2-Cyclopentylmethyl-3-methyl-5-(2-oxo-oxazolidin-3-yl)-1-
pyrrol-1-yl-pentane-1,5-dione—The title compound was prepared according to the
general procedure. anti 88% ee. anti isomer: IR (CH2Cl2) 2950, 2868, 1780, 1703, 1467,
1388, 1270, 1222, 1112, 1073, 1041, 745 cm−1; 1H NMR (300 MHz, CDCl3) δ 7.35 (br s,
2H, ArH), 6.30 (t, J=2.1 Hz, 2H, ArH), 4.39 (t, J=8.0 Hz, 2H, OCH2CH2N), 3.99 (t, J=8.2
Hz, 2H, OCH2CH2N), 3.23 (ddd, J=10.4, 5.9, 3.7 Hz, 1H, COCH(CH2c-penyl)CH), 3.12
(dd, J=17.0, 5.1 Hz, 1H, COCHHCH(CH3)C), 2.80 (dd, J=17.3, 8.0 Hz, 1H,
COCHHCH(CH3)C), 2.58–2.42 (m, 1H, CH2CH(CH3)C), 2.10–0.84 (m, 14H); 13C NMR
(75 MHz, CDCl3) δ 173.3, 172.1, 153.4, 119.2, 113.2, 62.0, 47.1, 42.5, 38.6, 38.3, 35.8,
33.3, 32.6, 32.4, 25.2, 25.1, 17.8; HRMS (EI) exact mass calcd for (C19H26N2O4) requires
m/z 346.1893, found m/z 346.1894. [α]D −8.0. Enantiomeric excess was determined by
HPLC analysis (OD-H and OD-H guard, 15% ethanol in hexanes, 1 mL/min); anti isomers
tR=10.8 and 15.2 min.
4.4.31. (3R,4S)-3-Methyl-5-oxo-4-phenyl-5-pyrrol-1-yl-pentanal (Table 3, entry
5)—The title compound was prepared according to the general procedure from
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crotonaldehyde (97 μL, 1.2 mmol), 1-(2-phenyl-1-trimethylsilanyloxy-vinyl)-1H-pyrrole (99
μL, 0.39 mmol), and (2S,5S)-5-benzyl-2-tert-butyl-3-methyl-imidazolidin-4-one·TfOH 1 (31
mg, 0.078 mmol) in CHCl3 (0.195 mL) and H2O (7.0 μL, 0.39 mmol) at −65 °C for 24 h.
The resulting residue was purified by silica gel chromatography (10% EtOAc/Hex) to
provide the pure product as an oil in 78% yield (78 mg, 0.31 mmol). 1:3 syn/anti. anti
isomer: IR (CH2Cl2) 1709, 1470, 1288, 914, 474 cm−1; 1H NMR (300 MHz, CDCl3) δ 9.75
(app br s, 1H, CHO), 7.40–7.20 (m, 7H, ArH), 6.25–6.20 (m, 2H, ArH), 4.12 (d, J=9.3 Hz,
1H, CHPh), 3.10–2.88 (m, 1H, CH2CH(CH3)C), 2.67 (app dd J=16.5, 3.3 Hz, 1H,
CHOCHHC), 2.49–2.35 (m, 1H, CHOCHHC), 0.85 (d, J=6.6 Hz, 3H, CH3); 13C NMR (75
MHz, CDCl3) δ 201.4, 201.2, 136.5, 129.2, 128.4, 128.1, 119.4,113.5, 56.2, 49.2, 32.2, 17.9;
HRMS (FAB) exact mass calcd for M+H (C16H18NO2) requires m/z 256.1338, found m/z
256.1349. [α]D −0.51. Diastereomeric ratios were determined by 1H NMR analysis.
Enantiomeric excess was determined by conversion to the corresponding acyl
oxazolidinone.
4.4.32. (2S,3R)-3-Methyl-5-(2-oxo-oxazolidin-3-yl)-2-phenyl-1-pyrrol-1-yl-
pentane-1,5-dione—The title compound was prepared according to the general
procedure. anti 87% ee. anti isomer: IR (CH2Cl2) 1778, 1705, 1469, 1388, 1270, 1116, 750,
702 cm−1; 1H NMR (300 MHz, CDCl3) δ 7.42–7.18 (m, 7H, ArH), 6.25–6.15 (m, 2H, ArH),
4.45–3.70 (m, 5H), 3.02–2.90 (m, 1H, COCHHC), 2.67 (dd, J=17.0, 7.5 Hz, 1H,
COCHHC), 1.29–1.18 (m, 1H), 1.15 (d, J=6.6 Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ
172.0, 170.4, 136.8, 129.0, 128.7, 127.9, 119.3, 113.2, 62.0, 56.2, 42.4, 40.2, 33.0, 19.1;
HRMS (EI) exact mass calcd for (C19H20N2O4) requires m/z 340.1423, found m/z 340.1434.
[α]D +0.76. Enantiomeric excess was determined by HPLC analysis (AD-H and AD-H
guard, 10% ethanol in hexanes, 1 mL/min); anti isomers tR=20.1 and 37.0 min and syn
isomers tR=23.2 and 28.5 min.
4.4.33. (3R,4R)-4-Benzyloxy-3-methyl-5-oxo-5-pyrrol-1-yl-pentanal (Table 3,
entry 6)—The title compound was prepared according to the general procedure from
crotonaldehyde (87 μL, 1.05 mmol), 1-(2-benzyloxy-1-trimethylsilanyloxy-vinyl)-1H-
pyrrole (97 μL, 0.35 mmol), and (2S,5S)-5-benzyl-2-tert-butyl-3-methyl-imidazolidin-4-
one·TBA 1 (38 mg, 0.070 mmol) in THF (0.175 mL) and H2O (6.3 μL, 0.35 mmol) at −78
°C for 22 h. The resulting residue was purified by silica gel chromatography (10% EtOAc/
Hex) to provide the pure product as an oil in 69% yield (69 mg, 0.24 mmol).1:42 syn/anti.
anti isomer: IR (CH2Cl2) 1720, 1469, 1318, 1295, 1099, 1076, 745, 699 cm−1; 1H NMR
(300 MHz, CDCl3) δ 9.58 (t, J=1.6 Hz, 1H, CHO), 7.43–7.05 (m, 7H, ArH), 6.20–6.05 (m,
2H, ArH), 4.48 (d, J=11.4 Hz, 1H, OCHHPh), 4.22 (d, J=11.4 Hz, 1H, OCHHPh), 4.05 (d,
J=7.7 Hz, 1H, COCH(OBn)C), 2.62–2.41 (m, 2H, CHOCH2), 2.28 (td, J=8.5, 1.6 Hz, 1H,
CH2CH(CH3)CH), 0.85 (d, J=6.7 Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 200.9,
169.5, 136.3, 128.5, 128.3, 128.3, 119.5, 113.5, 83.9, 72.6, 47.3, 32.3, 16.8; HRMS (EI)
exact mass calcd for (C17H19NO3) requires m/z 285.1365, found m/z 285.1358. [α]D −39.8.
Diastereomeric ratios and enantiomeric excess were determined by HPLC analysis of the
corresponding acyl oxazolidinone.
Borths et al. Page 14
Tetrahedron. Author manuscript; available in PMC 2014 September 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4.4.34. (2R,3R)-2-Benzyloxy-3-methyl-5-(2-oxo-oxazolidin-3-yl)-1-pyrrol-1-yl-
pentane-1,5-dione—The title compound was prepared according to the general
procedure.12 anti 93% ee. All spectral data were in agreement with those previously
reported.
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Table 1
Investigation of latent enolates with crotonaldehyde
Entry XR % Conversiona syn/antib % eeb,c
1 Ot-Bu 0 — —
2 SPh 0 — —
3 SMe 38 3.2:1 91
4 SEt 43 2.6:1 86
5 S-i-Pr 70 5.8:1 90
6 S-t-Bu 38 5.4:1 88
7 1-Pyrrolyld 92 1:17 83
a
Product ratios determined by chiral GLC.
b
Determined by HPLC analysis of the corresponding acyl oxazolidine.
c
Enantiomeric excess of the major diastereomer.
d
Performed with the (E)-silylketene acetal and the trichloroacetic acid salt of catalyst 1.
Tetrahedron. Author manuscript; available in PMC 2014 September 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Borths et al. Page 18
Ta
bl
e 
2
Sy
nt
he
sis
 o
f s
yn
-
M
uk
ai
ya
m
a–
M
ic
ha
el
 a
dd
uc
ts:
 sc
op
e
En
tr
ya
Si
R
3
R
1
R
2
%
 Y
ie
ld
sy
n/
a
n
tib
%
 ee
c
1
TB
S
M
e
M
e
76
10
:1
90
2
TB
S
M
e
n
-
Pr
62
6:
1
90
3
TM
S
M
e
Ph
50
20
:1
90
d
4
TB
S
M
e
CO
2M
e
73
4:
1
91
5
TB
S
Et
M
e
76
4:
1
94
6
TB
S
O
Bn
M
e
82
>
20
:1
90
d
a
A
bs
ol
ut
e 
an
d 
re
la
tiv
e 
co
nf
ig
ur
at
io
n 
as
sig
ne
d 
by
 d
er
iv
iti
za
tio
n 
an
d 
X
RD
 a
na
ly
sis
 o
r b
y 
an
al
og
y.
b D
et
er
m
in
ed
 b
y 
1 H
 N
M
R 
an
al
ys
is.
c D
et
er
m
in
ed
 b
y 
H
PL
C 
an
al
ys
is 
of
 th
e 
co
rre
sp
on
di
ng
 a
cy
l o
xa
zo
lid
in
e.
d T
FA
 c
oc
at
al
ys
t.
Tetrahedron. Author manuscript; available in PMC 2014 September 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Borths et al. Page 19
Ta
bl
e 
3
Sy
nt
he
sis
 o
f a
n
ti-
M
uk
ai
ya
m
a–
M
ic
ha
el
 a
dd
uc
ts:
 sc
op
e
En
tr
ya
R
1
R
2
H
X
%
 Y
ie
ld
sy
n/
a
n
tib
%
 ee
c
1
M
e
M
e
TC
A
92
1:
17
83
2
M
e
n
-
Pr
2,
4-
D
N
BA
d
55
1:
4
93
3
M
e
p-
Cl
Ph
TF
A
74
1:
3
98
4
CH
2c
yc
lo
pe
nt
yl
M
e
TB
A
68
1:
10
88
e
5
Ph
M
e
Tf
O
H
78
1:
3
87
6
O
Bn
M
e
TB
A
69
1:
>2
0
93
a
A
bs
ol
ut
e 
an
d 
re
la
tiv
e 
ste
re
oc
he
m
ist
ry
 a
ss
ig
ne
d 
by
 c
he
m
ic
al
 c
or
re
la
tio
n 
to
 p
ro
du
ct
s o
f T
ab
le
 3
 o
r b
y 
an
al
og
y.
b D
et
er
m
in
ed
 b
y 
1 H
 N
M
R 
an
al
ys
is.
c D
et
er
m
in
ed
 b
y 
H
PL
C 
an
al
ys
is 
of
 th
e 
co
rre
sp
on
di
ng
 a
cy
l o
xa
zo
lid
in
e.
d 2
,4
-D
N
BA
=2
,4
-d
in
itr
ob
en
zo
ic
 a
ci
d.
e D
et
er
m
in
ed
 b
y 
G
LC
 a
na
ly
sis
.
Tetrahedron. Author manuscript; available in PMC 2014 September 09.
